SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- Medical technology company Zynex, Inc. (NASDAQ: ZYXI) is facing a double whammy linked to its dealings with TriCare, the healthcare program for the U.S. military community. The company's first-quarter 2025 results revealed a sharp downturn, largely attributed to a temporary payment suspension by one of its major payers, TriCare. Adding to the company’s troubles, this very TriCare payment issue has now become central to a recently announced class action lawsuit ...

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI). Shareholders who purchased shares of ZYXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form/?id=147129&from=3 CLASS PERIOD: March 13, 2023 to March ...

NEW YORK, May 6, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zynex, Inc. ("Zynex, Inc." or the "Company") (NASDAQ: ZYXI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zynex, Inc. investors who were adversely affected by alleged securities fraud between March 13, 2023 and March 11, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-form? ...

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zynex, Inc. ("Zynex, Inc." or the "Company") (NASDAQ: ZYXI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zynex, Inc. investors who were adversely affected by alleged securities fraud between March 13, 2023 and March 11, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/zynex-inc-lawsuit-submissio ...

Core Viewpoint - Zynex, Inc. is facing allegations of issuing materially false and misleading statements, which may have led to inflated revenues and potential penalties from insurers and the federal government [1][2]. Group 1: Allegations - The complaint alleges that Zynex shipped products, including electrodes, in excess of need, resulting in inflated revenue [1]. - The company's practice of filing false claims has drawn scrutiny from insurers, including the U.S. military health insurance program, Tricare [1]. - There is a reasonable likelihood that Zynex will face adverse consequences, including removal from insurer networks and penalties from the federal government [1]. Group 2: Class Action Details - The class period for the allegations is from March 13, 2023, to March 11, 2025 [1]. - Shareholders who purchased shares of ZYXI during this period are encouraged to register for the class action by May 19, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive status updates throughout the lifecycle of the case [2]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who incurred losses from misleading statements [3].

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zynex, Inc. ("Zynex, Inc." or the "Company") (NASDAQ: ZYXI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zynex, Inc. investors who were adversely affected by alleged securities fraud between March 13, 2023 and March 11, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/zynex-inc-lawsuit-submissio ...

NEW YORK, May 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zynex, Inc. ("Zynex, Inc." or the "Company") (NASDAQ: ZYXI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zynex, Inc. investors who were adversely affected by alleged securities fraud between March 13, 2023 and March 11, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-form? ...

NEW YORK, May 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI).Shareholders who purchased shares of ZYXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form/?id=146161&from=4 CLASS PERIOD: March 13, 2023 to March 11, 2025 ...

Financial Data and Key Metrics Changes - Net revenue for Q1 2025 was $26.6 million, a decrease from $46.5 million in Q1 2024, primarily due to a temporary payment suspension from TRICARE and slowing order growth [20][21] - Gross profit in Q1 2025 was $18.2 million, representing 69% of revenue, compared to $37.2 million or 80% of revenue in Q1 2024 [20][21] - Net loss for Q1 2025 was $10.4 million, or $0.33 per share, compared to a net income of $10,000 in the previous year [21][22] Business Line Data and Key Metrics Changes - Device revenue was $11.9 million, while supplies revenue was $14.7 million in Q1 2025 [20] - Non-NexWave product order percentage increased to 34% in Q1 2025, up from an average of 30% in the previous year [13] Market Data and Key Metrics Changes - The company is experiencing a temporary payment suspension from TRICARE, which has affected revenue recognition [6][12] - The patient monitoring market is identified as a multibillion-dollar opportunity, with the company planning to enter with a superior product [19] Company Strategy and Development Direction - The company is restructuring to operate without TRICARE business in a worst-case scenario and is focusing on new revenue opportunities [9][10] - The company aims to generate revenue exceeding $800 million annually in the long term [25] - The launch of the Nico pulse oximeter is anticipated to significantly impact the patient monitoring market, with a focus on improving health equity [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth prospects despite current challenges, emphasizing a commitment to high-quality service and technology [24][25] - The company expects to receive a response from TRICARE regarding the payment suspension within 40 days [24] Other Important Information - The company has reduced overall staff by approximately 15%, primarily in the corporate office, which is expected to result in annual savings of about $35 million [13] - The company maintains a strong balance sheet with $40 million in working capital and approximately $24 million in cash [22] Q&A Session Summary Question: Insights into TRICARE conversations and potential domino effects - Management indicated that the claims from TRICARE were vague and emphasized compliance with guidelines, stating there are no current issues with other payers [28][30][31] Question: Clarification on Q1 revenue miss and future guidance - The revenue miss was attributed to multiple factors, and management is waiting for clarity on TRICARE before providing full-year guidance [32][34][35] Question: Confirmation of TRICARE payments in Q1 and Q2 guidance - Management confirmed that Q1 revenue and guidance for Q2 do not include TRICARE payments, and they expect reimbursement for claims once the suspension is lifted [37][38] Question: Plans if TRICARE outcome is negative - The company plans to refocus its sales force to generate revenue from other areas if TRICARE payments are not restored [40][41] Question: Expected revenue from Nico post-approval - Management expects to launch Nico immediately upon FDA clearance, with revenue anticipated in 2026 [42]

Core Viewpoint - Zynex, Inc. is facing a class action lawsuit due to allegations of misleading statements and improper business practices that have led to significant financial losses for investors during the specified class period [3][4][5]. Group 1: Allegations and Lawsuit Details - The class action lawsuit claims that Zynex shipped medical products in quantities exceeding patient needs, resulting in inflated revenue figures [3]. - The lawsuit highlights that Zynex's practices attracted scrutiny from insurers, including Tricare, which could lead to negative consequences such as exclusion from insurer networks and potential penalties from federal agencies [3]. - A report published by STAT accused Zynex of operating an "oversupplying scheme," sending excessive quantities of supplies to bill insurers unjustifiably, which contributed to a decline in Zynex's stock price by over 5% following its release [4]. Group 2: Financial Impact - On March 11, 2025, Zynex announced a revenue shortfall for Q4 and full year 2024, attributing it to slower payments from certain payers, which included a temporary suspension of payments from Tricare pending a review of previous claims [5]. - Following the announcement of the revenue shortfall, Zynex's stock price plummeted by more than 51% [5].